Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer

Lee, 2016, NRG Oncology RTOG 0415: A randomized phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer, Int J Radiat Oncol Biol Phys, 94, 3, 10.1016/j.ijrobp.2015.10.049 Aluwini, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial, Lancet Oncol, 17, 464, 10.1016/S1470-2045(15)00567-7 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4 Catton, 2017, Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, J Clin Oncol, 35, 1884, 10.1200/JCO.2016.71.7397 Arcangeli, 2017, Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial, J Clin Oncol, 35, 1891, 10.1200/JCO.2016.70.4189 Pollack, 2013, Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, J Clin Oncol, 31, 3860, 10.1200/JCO.2013.51.1972 Gonzalez-Motta, 2018, Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?, Pract Radiat Oncol, 8, 185, 10.1016/j.prro.2017.11.008 Tyagi, 2017, Clinical workflow for MR-only simulation and planning in prostate, Radiat Oncol, 12, 119, 10.1186/s13014-017-0854-4 Tyagi, 2017, Dosimetric and workflow evaluation of first commercial synthetic CT software for clinical use in pelvis, Phys Med Biol, 62, 2961, 10.1088/1361-6560/aa5452 Ashman, 2005, Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy, Int J Radiat Oncol Biol Phys, 63, 765, 10.1016/j.ijrobp.2005.02.050 Kaidar-Person, 2013, Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: A step forward, Int J Radiat Oncol Biol Phys, 86, 600, 10.1016/j.ijrobp.2013.02.006 Musunuru, 2018, Phase I/II study of stereotactic ablative radiotherapy including regional lymph node irradiation for patients with high-risk prostate cancer (SATURN): Early results, Int J Radiat Oncol Biol Phys, 10.1016/j.ijrobp.2018.07.2005 Lyons, 2016, SPORT high-risk trial: A randomised feasibility study evaluating stereotactic prostate radiotherapy in high-risk localised prostate cancer with or without elective nodal irradiation, Eur J Surg Oncol, 42, S235, 10.1016/j.ejso.2016.07.076 Murthy, 2018, Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer, Clin Oncol (R Coll Radiol), 30, 442, 10.1016/j.clon.2018.03.004 Bauman, 2015, A phase 1/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 92, 856, 10.1016/j.ijrobp.2015.02.046 Hamstra, 2017, Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial, Int J Radiat Oncol Biol Phys, 97, 976, 10.1016/j.ijrobp.2016.12.024 Kang, 2011, Image-guided stereotactic body radiation therapy for localized prostate cancer, Tumori, 97, 43, 10.1177/030089161109700109 King, 2013, Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials, Radiother Oncol, 109, 217, 10.1016/j.radonc.2013.08.030 Katz, 2016, Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: Risk-stratification and patterns of failure, Front Oncol, 6, 168, 10.3389/fonc.2016.00168 Bolzicco, 2013, A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy, BMC Urol, 13, 49, 10.1186/1471-2490-13-49 Chen, 2013, Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience, Radiat Oncol, 8, 58, 10.1186/1748-717X-8-58 Lee, 2014, Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: A 5-year follow-up of an investigational study, Medicine (Baltimore), 93, e290, 10.1097/MD.0000000000000290 Bernetich, 2014, SBRT for the primary treatment of localized prostate cancer: The effect of gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines, Front Oncol, 4, 312, 10.3389/fonc.2014.00312 Davis, 2015, Stereotactic body radiotherapy for clinically localized prostate cancer: Toxicity and biochemical disease-free outcomes from a multi-institutional patient registry, Cureus, 79, e395 Ricco, 2016, The comparison of stereotactic body radiation therapy and intensity-modulated radiation therapy for prostate cancer by NCCN risk groups, Front Oncol, 6, 184, 10.3389/fonc.2016.00184 Kotecha, 2016, Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: Initial dosimetry analysis and patient outcomes, Int J Radiat Oncol Biol Phys, 95, 960, 10.1016/j.ijrobp.2016.02.009 Koskela, 2017, Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience, Acta Oncol, 56, 978, 10.1080/0284186X.2017.1288923